Supplying clotting factors from hematopoietic stem cell-derived erythroid and megakaryocytic lineage cells

Molecular Therapy

Volumn 17, Issue 12, 2009, Pages 1994-1999

  Sadelain, Michel ^a   Chang, Alex ^a   Lisowski, Leszek ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; ANGIOGENESIS INHIBITOR; ANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BUSULFAN; CARMUSTINE; ERYTHROPOIETIN; GLOBIN; GLYCOPROTEIN IIB; GROWTH FACTOR; PARATHYROID HORMONE; PROTEIN; PROTEIN DERIVATIVE; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR; VIRUS VECTOR;

BLEEDING; BLOOD CLOTTING FACTOR DEFICIENCY; CANCER RISK; CELL FUNCTION; CELL LINEAGE; CHIMERA; ENGRAFTMENT; ENZYME DEFICIENCY; ERYTHROBLAST; ERYTHROID CELL; EXPRESSION VECTOR; GENE EXPRESSION; GENE INSERTION; GENE SILENCING; GENETIC ENGINEERING; GENOTOXICITY; HEMATOPOIETIC STEM CELL; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOTOXICITY; LONG TERMINAL REPEAT; LYSOSOME STORAGE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MAMMAL; MEGAKARYOCYTE; MUTAGENESIS; NONHUMAN; NONMYELOABLATIVE CONDITIONING; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PLURIPOTENT STEM CELL; PROGENY; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; THROMBOCYTE; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM;

MAMMALIA;

EID: 73849116439     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.238     Document Type: Review

References (68)

1. Dunbar, CE (1996). Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Annu Rev Med 47: 11-20.
2. Chang, AH and Sadelain, M (2007). The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Mol Ther 15: 445-456.
3. Nienhuis, AW (2008). Development of gene therapy for blood disorders. Blood 111: 4431-4444.
4. Biff, A and Cesani, M (2008). Human hematopoietic stem cells in gene therapy: pre-clinical and clinical issues. Curr Gene Ther 8: 135-146.
5. Murphy, SL and High, KA (2008). Gene therapy for haemophilia. Br J Haematol 140: 479-487.
6. Shizuru, JA, Negrin, RS and Weissman, IL (2005). Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med 56: 509-538.
7. Hacein-Bey-Abina, S, Le Deist, F, Carlier, F, Bouneaud, C, Hue, C, De Villartay, JP et al. (2002). Sustained correction of X-linked severe combined immunodefciency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
8. Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. (2009). Gene therapy for immunodefciency due to adenosine deaminase defciency. N Engl J Med 360: 447-458.
9. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
10. Hacein-Bey-Abina, S, Garrigue, A, Wang, G P, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
11. Nair, V (2008). Retrovirus-induced oncogenesis and safety of retroviral vectors. Curr Opin Mol Ther 10: 431-438.
12. Kohn, DB, Sadelain, M and Glorioso, JC (2003). Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 3: 477-488.
13. von Kalle, C, Baum, C and Williams, DA (2004). Lenti in red: progress in gene therapy for human hemoglobinopathies. J Clin Invest 114: 889-891.
14. High, K (2005). Gene transfer for hemophilia: can therapeutic effcacy in large animals be safely translated to patients? J Thromb Haemost 3: 1682-1691.
15. Mingozzi, F and High, KA (2007). Immune responses to AAV in clinical trials. Curr Gene Ther 7: 316-324.
16. Pierce, GF, Lillicrap, D, Pipe, SW and Vandendriessche, T (2007). Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J Thromb Haemost 5: 901-906.
17. Hoeben, RC, Einerhand, M P, Briët, E, van Ormondt, H, Valerio, D and van der Eb, AJ (1992). Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 67: 341-345.
18. Evans, GL and Morgan, RA (1998). Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci USA 95: 5734-5739.
19. Moayeri, M, Ramezani, A, Morgan, RA, Hawley, TS and Hawley, RG (2004). Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther 10: 892-902.
20. Kootstra, NA, Matsumura, R and Verma, IM (2003). Effcient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther 7(5 Pt 1): 623-631.
21. Kikuchi, J, Mimuro, J, Ogata, K, Tabata, T, Ueda, Y, Ishiwata, A et al. (2004). Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodefciency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice. J Gene Med 6: 1049-1060.
22. Tiede, A, Eder, M, von Depka, M, Battmer, K, Luther, S, Kiem, HP et al. (2003). Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther 10: 1917-1925.
23. Bigger, BW, Siapati, EK, Mistry, A, Waddington, SN, Nivsarkar, MS, Jacobs, L et al. (2006). Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther 13: 117-126.
24. Chang, AH, Stephan, MT and Sadelain, M (2006). Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol 24: 1017-1021.
25. Mohamedali, A, Moreau-Gaudry, F, Richard, E, Xia, P, Nolta, J and Malik, P (2004). Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells. Mol Ther 10: 249-259.
26. Ellis, J (2005). Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 16: 1241-1246.
27. Moayeri, M, Hawley, TS and Hawley, RG (2005). Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol Ther 12: 1034-1042.
28. Ide, LM, Gangadharan, B, Chiang, KY, Doering, CB and Spencer, HT (2007). Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood 110: 2855-2863.
29. Doering, CB, Gangadharan, B, Dukart, HZ and Spencer, HT (2007). Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity. Mol Ther 15: 1093-1099.
30. Rodriguez, MH, Enjolras, N, Plantier, JL, Réa, M, Leboeuf, M, Uzan, G et al. (2002). Expression of coagulation factor IX in a haematopoietic cell line. Thromb Haemost 87: 366-373.
31. Shi, Q, Wilcox, DA, Fahs, SA, Kroner, PA and Montgomery, RR (2003). Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. Mol Genet Metab 79: 25-33.
32. Yarovoi, HV, Kufrin, D, Eslin, DE, Thornton, MA, Haberichter, SL, Shi, Q et al. (2003). Factor VIII ectopically expressed in platelets: effcacy in hemophilia A treatment. Blood 102: 4006-4013.
33. Shi, Q, Wilcox, DA, Fahs, SA, Fang, J, Johnson, BD, DU, LM et al. (2007). Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 5: 352-361.
34. Shi, Q, Fahs, SA, Wilcox, DA, Kuether, EL, Morateck, PA, Mareno, N et al. (2008). Syngeneic transplantation of hematopoietic stem cells that are genetically modifed to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood 112: 2713-2721.
35. Ohmori, T, Ishiwata, A, Kashiwakura, Y, Madoiwa, S, Mitomo, K, Suzuki, H et al. (2008). Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets. Mol Ther 16: 1359-1365.
36. Shi, Q, Wilcox, DA, Fahs, SA, Weiler, H, Wells, CW, Cooley, BC et al. (2006). Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 116: 1974-1982.
37. Gewirtz, J, Thornton, MA, Rauova, L and Poncz, M (2008). Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J Thromb Haemost 6: 1160-1166.
38. May, C, Rivella, S, Callegari, J, Heller, G, Gaensler, KM, Luzzatto, L et al. (2000). Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 406: 82-86.
39. Lisowski, L and Sadelain, M (2008). Current status of globin gene therapy for the treatment of beta-thalassaemia. Br J Haematol 141: 335-345.
40. Sadelain, M, Boulad, F, Lisowki, L, Moi, P and Riviere, I (2008). Stem cell engineering for the treatment of severe hemoglobinopathies. Curr Mol Med 8: 690-697.
41. Chang, AH, Stephan, MT, Lisowski, L and Sadelain, M (2008). Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Mol Ther 16: 1745-1752.
42. Rohrbach, M and Clarke, JT (2007). Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 67: 2697-2716.
43. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16: 718-725.
44. Ryu, BY, Evans-Galea, MV, Gray, JT, Bodine, DM, Persons, DA and Nienhuis, AW (2008). An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 111: 1866-1875.
45. Levings, PP, Zhou, Z, Vieira, KF, Crusselle-Davis, VJ and Bungert, J (2006). Recruitment of transcription complexes to the beta-globin locus control region and transcription of hypersensitive site 3 prior to erythroid differentiation of murine embryonic stem cells. FEBS J 273: 746-755.
46. Hargrove, PW, Kepes, S, Hanawa, H, Obenauer, JC, Pei, D, Cheng, C et al. (2008). Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 16: 525-533.
47. Wallace, JA and Felsenfeld, G (2007). We gather together: insulators and genome organization. Curr Opin Genet Dev 17: 400-407.
48. Rivella, S, Callegari, JA, May, C, Tan, CW and Sadelain, M (2000). The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol 74: 4679-4687.
49. Emery, DW, Yannaki, E, Tubb, J and Stamatoyannopoulos, G (2000). A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci USA 97: 9150-9155.
50. Baum, C, Düllmann, J, Li, Z, Fehse, B, Meyer, J, Williams, DA et al. (2003). Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101: 2099-2114. (Pubitemid 36302043)
51. Li, CL, Xiong, D, Stamatoyannopoulos, G and Emery, DW (2009). Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of thecHS4 chromatin insulator. Mol Ther 17: 716-724.
52. Desprat, R and Bouhassira, EE (2009). Gene specificity of suppression of transgene-mediated insertional transcriptional activation by the chicken HS4 insulator. PLoS ONE 4: e5956.
53. Hanawa, H, Yamamoto, M, Zhao, H, Shimada, T and Persons, DA (2009). Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. Mol Ther 17: 667-674.
54. Pikaart, MJ, Recillas-Targa, F and Felsenfeld, G (1998). Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev 12: 2852-2862.
55. D'Apolito, D, Baiamonte, E, Bagliesi, M, Di Marzo, R, Calzolari, R, Ferro, L et al. (2009). The sea urchin sns5 insulator protects retroviral vectors from chromosomal position effects by maintaining active chromatin structure. Mol Ther 17: 1434-1441.
56. Graves, SS, Stone, D, Loretz, C, Peterson, L, McCune, JS, Mielcarek, M et al. (2009). Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig. Transplantation 88: 317-322.
57. Yeoman, H and Mellor, AL (1992). Tolerance and MHC restriction in transgenic mice expressing a MHC class I gene in erythroid cells. Int Immunol 4: 59-65.
58. Seledtsova, GV, Seledtsov, VI, Samarin, DM, Senyukov, VV, Ivanova, I P, Akimenko, ZA et al. (2004). Erythroid cells in immunoregulation: characterization of a novel suppressor factor. Immunol Lett 93: 171-178.
59. Barker, RN, Vickers, MA and Ward, FJ (2007). Controlling autoimmunity-Lessons from the study of red blood cells as model antigens. Immunol Lett 108: 20-26.
60. Daren Wang, Wei Zhang, Theodosia Kalfa, Gregory Grabowski, Stella Davies, Punam Malik et al.Lysosomal enzyme in red: redirecting erythroid cells for production of a lysosomal enzyme leads to long-term higher-than normal levels of functional enzyme in circulation with therapeutic correction in primary and secondary MPS type I recipient mice [abstr.]. Mol Ther 31.
61. Claudia Montiel-Equihua, Monkeviciute Aiste, Antoniou Michael, Thrasher Adrian and Gaspar Bobby. Towards the development of an improved vector for SCID-ADA gene therapy [abstr.]. Mol Ther 82.
62. Dooriss KL, Sutherland ND, Spencer NT. Lentiviral gene transfer of erythroid-specific promoters drives high-level fVIII expression from gene-modifed hematopoietic stem and progenitor cells. Mol Ther 627.
63. Migliaccio, AR, Whitsett, C and Migliaccio, G (2009). Erythroid cells in vitro: from developmental biology to blood transfusion products. Curr Opin Hematol 16:259-268.
64. Strulovici, Y, Leopold, PL, O'Connor, TP, Pergolizzi, RG and Crystal, RG (2007). Human embryonic stem cells and gene therapy. Mol Ther 15: 850-866.
65. Srivastava, AS, Malhotra, R, Esmaeli-Azad, B, Lane, T and Carrier, E (2007). Prospects of embryonic stem cells in treatment of hematopoietic disorders. Curr Pharm Biotechnol 8: 305-317.
66. Mountford, JC (2008). Human embryonic stem cells: origins, characteristics and potential for regenerative therapy. Transfus Med 18: 1-12.
67. Liu, SV (2008). iPS cells: a more critical review. Stem Cells Dev 17: 391-397.
68. Yamanaka, S (2009). A fresh look at iPS cells. Cell 137: 13-17.